Realize true social contribution through the development of " the best possible products to protect the health and wellbeing of the people. "
Drug Development and Regulatory Science Division
Senior Vice President, Dr. Takeki Uehara
In 2002, joined SHIONOGI & Co., Ltd.
Engaged in toxicology research of candidate medicines under development at the Drug Development Research Division / Drug Safety Department.
In 2009, after completing a carrier as a visiting researcher for Public Health research at University of North Carolina at Chapel Hill in the United States, was mainly involved in global development projects as a non-clinical toxicity expert in Shionogi HQ.
In 2013, transferred to the Drug Development and Regulatory Science Division. Successively held the posts of Non-clinical leader of anti-influenza virus drug XOFLUZA, global project leader after obtaining Proof of Concept.
In 2020, transferred to USA Shionogi Inc. Head of Clinical Development Department
In 2021, concurrently serves as Vice President of Clinical Research Department, Global Head of Clinical Operations, and Global Project Leader for S-217622, an oral treatment for COVID-19.
In July 2022, appointed as Senior Vice President of Drug Development and Regulatory Science Division (current position).